myTomorrows Raises €25 Million To Expand Global Patient Access To Treatments

Avego’s growth equity investment will support the global expansion of myTomorrows’ integrated pharma solutions, helping make emerging treatments more equitable and accessible for patients worldwide.

“This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow’s therapies,” said Michel van Harten, CEO of myTomorrows. “Avego’s extensive expertise in life sciences, particularly BioPharma, will be instrumental as we scale our platform and broaden our impact across the global health landscape.”

This growth equity investment in myTomorrows comes amid a wave of significant 2025 HealthTech funding rounds across Europe.

Read Also - Spain’s Amenitiz Hits 15,000+ hotels And €3B Bookings With New Funding

This growth-equity investment in myTomorrows aligns with several notable European HealthTech funding rounds in 2025.

In Belgium, Sequana Medical secured €24 million to support the U.S. launch of its “alfapump” device for chronic fluid-retention management. In France, ArcaScience raised €6 million to enhance AI-driven benefit-risk intelligence for drug development. Meanwhile, Finland’s CurifyLabs obtained €6.7 million to modernize the production of personalized medicines.

While these companies operate in adjacent segments of the broader HealthTech and BioPharma landscape, myTomorrows distinguishes itself by focusing on patient access to pre-approval therapies through an AI-enabled platform that connects physicians, trial sites, and biopharma partners.

The company’s round represents one of the more substantial Dutch HealthTech financings reported in 2025, highlighting continued investor confidence in technology solutions that bridge early-stage drug development and patient access.

Ronald Brus, Founder and Board Member of myTomorrows, added: “When we founded myTomorrows in 2012, we envisioned a better way to connect patients with promising therapies – one that complements drug development and expands access to innovation. This investment marks the beginning of a next phase of accelerated growth and worldwide impact.”

Founded in 2012, myTomorrows is a global HealthTech company connecting patients, physicians, trial sites, and BioPharma partners to enable earlier and better access to pre-approval treatments.

Through a centralized, multi-stakeholder platform, myTomorrows combines AI-driven insights with human expertise to deliver tailored solutions that overcome key barriers to patient access.

Headquartered in Amsterdam, with an office in New York City, myTomorrows has supported over 16,900 patients and 2,800 physicians across 340+ sites in more than 133 countries.

With over 300 million patients worldwide facing conditions without approved treatments and more than 10,000 therapies in development or awaiting approval myTomorrows addresses one of healthcare’s most urgent challenges: bridging the gap between scientific advancement and patient access to pre-approval treatments, including clinical trials and expanded access programs (EAPs).

The new investment will accelerate international growth, further develop its AI-driven platform, and strengthen collaborations with industry partners to streamline access, generate real-world evidence, and shorten clinical development timelines.

“Avego is proud to support myTomorrows in its mission to transform how patients and physicians access therapies in development,” said James Flexner, Managing Partner at Avego. “We believe myTomorrows is uniquely positioned to remove barriers for patients and providers while serving as an essential partner to BioPharma.”

For BioPharma partners, myTomorrows provides clinical trial recruitment, expanded access solutions, and real-world data collection. For trial sites, the platform offers a unified referral management system that increases trial visibility and delivers real-time status updates.

myTomorrows has also gained recognition from EU-Startups, which first covered its €10 million funding round in 2017 and later featured the company in its 2021 roundup of top healthcare startups in the Netherlands.

About myTomorrows

myTomorrows helps patients discover and access treatments through a single digital platform that connects all stakeholders. They guide patients and physicians on clinical trials and expanded access programs, providing free Patient Navigator support, while supporting BioPharma partners with trial recruitment, global access program management, and real-world data collection.